The first domestic epothilone tumor drug may be born: a new breast cancer class 1 drug "under approval"

A few days ago, the review status of utidelone (UTD1)'s new drug marketing application on the NMPA official website was updated to "under approval", or it is expected to be approved for the treatment of recurrent and metastatic advanced breast cancer in the near future .

If it is successfully approved, it will become the first epothilone anti-tumor drug in China.

Epothilone drugs are broad-spectrum and high-efficiency anti-cancer drugs.

It is understood that the new drug listing application of Utidrolone is based on the results of a prospective, multi-center phase III clinical study.

The specific research data are as follows: For patients with advanced breast cancer who have used anthracyclines and taxanes in the past, the overall survival of Utidrolone combined with capecitabine and capecitabine alone was 15.

At present, anthracyclines and taxanes are still the main drugs used in chemotherapy for advanced breast cancer.

Data for 2020 show that breast cancer has replaced lung cancer as the world's largest cancer.